Choose a country to view content specific to your location

EBV

Epstein–Barr virus (EBV), also called human herpesvirus 4 (HHV-4), is a virus of the herpes family and infects more than 95% of the world’s population. The most common disease from primary infection is acute infectious mononucleosis, a self-limiting illness that frequently affects adolescents and young adults.

Have questions about a product?

Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!

Product Filters
Type
Recombinant
Format
Host/Source
Tested Apps
Clear All

EBV Products (16)

Filters Close
NameTypeFormatHost/SourceIsotypeTested AppsUnitCatalogBufferImmunogenRecombinantDescriptionNotesSafety Data SheetCOA/Test ReleaseProduct Information SheetNew ProductRecommended ProductOrder a Sample
MAb to Epstein Barr Virus MonoclonalPurifiedMouseIgG1,kEIA,IFA,WBMGC66405M10 mM Sodium Phosphate, 150 mM Sodium Chloride, pH 7.4 ± 0.2Purified gp 125NoMAb to Epstein Barr Virus Monoclonal Antibody to Epstein Barr Virus (EBV - VCA) Viral Capsid Antigen gp 125Safety Data Sheet
COA/Test Release0
EBV-VCA Gp125, Purified Ag AntigenPurifiedCell CultureN/AEIA,WB,LF,CLIML820220 mM Tris-HCl, pH 7.4 containing 3 M Magnesium Chloride.NoEBV-VCA gp125, Purified Ag Epstein-Barr Viral Capsid (EBV-VCA) gp125 Antigen, PurifiedSafety Data Sheet
COA/Test Release0
EBV (HHV-4) Ea-d Recombinant AntigenPurifiedE. coliN/AEIA,WBMGR1874050 mM Tris-HCl, pH 8, 10 mM Glutathione, 60 mM Sodium Chloride, 0.5% Sarcosyl, 50% Glycerol.YesEBV (HHV-4) EA-D Recombinant Epstein Barr Virus (EBV) (HHV-4) Early Antigen D (EA-D), RecombinantSafety Data Sheet
COA/Test Release0
EBV antigen P3h3 AntigenLysateP3H3 CellsN/AEIAMLR02100Tris with NP40, Sodium Deoxycholate and PMSF.NoEBV Antigen Epstein Barr Virus (EBV) AntigenSafety Data Sheet
COA/Test Release0
EBV EBNA-1, Recombinant AntigenPurifiedE. coliN/AEIA,WB,CLIMGR0167220 mM Phosphate Buffer, pH 8, 5mM EDTA and 0.15 M Sodium Chloride.YesEBV EBNA-1, Recombinant Epstein-Barr Virus (EBV) Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1), RecombinantSafety Data Sheet
COA/Test Release0
EBV Vca P23 Recombinant AntigenPurifiedE. coliN/AEIA,WBMGR01570Lyophilized from 20 mM Phosphate Buffer, pH 8, 0.7 M Sodium Chloride and 0.1% Polyoxyethylene (10) Tridecyl Ether.YesEBV VCA p23 Recombinant Epstein-Barr Virus (EBV) Viral Capsid Antigen (VCA) p23, RecombinantSafety Data Sheet
COA/Test Release0
EBV Vca P18 Recombinant AntigenPurifiedE. coliN/AEIA,WBMGR0157120 mM Phosphate Buffer, pH 7, 1 M Sodium Chloride and 0.1% Polyoxyethylene (10) Tridecyl Ether.YesEBV VCA p18 Recombinant Epstein-Barr Virus (EBV) Viral Capsid Antigen (VCA) p18, RecombinantSafety Data Sheet
COA/Test Release0
EBV P54 (ea-d) Recombinant AntigenPurifiedE. coliN/AEIA,WBMGR0157550 mM 2-(N-Morpholino)Ethanesulfonic Acid (MES), pH 7, 0.1 M Potassium Chloride (KCl) and 0.1% Polyoxyethylene (10) Tridecyl EtherYesEBV p54 (EA-D) Recombinant Epstein-Barr Virus (EBV) p54, Early Antigen D (EA-D), RecombinantSafety Data Sheet
COA/Test Release0
EBV Ebna-1, Recombinant AntigenPurifiedE. coliN/AEIA,WB,CLIMGR015226 M Urea, 20 mM Phosphate, pH 8.0, 1 M Sodium Chloride, 0.1% Polyoxyethylene (10) Tridecylether.YesEBV EBNA-1, Recombinant Epstein-Barr Virus (EBV) Nuclear Antigen-1 (EBNA-1), RecombinantSafety Data Sheet
COA/Test Release0
EBV P138 (ea-d) Recombinant AntigenPurifiedE. coliN/AEIA,WBMGR015256 M Urea, 20 mM Phosphate, pH 8, 0.15 M Sodium Chloride, 0.1% Polyoxyethylene(10)Tridecylether.YesEBV p138 (EA-D) Recombinant Epstein-Barr Virus (EBV) p138, Early Antigen D (EA-D), RecombinantSafety Data Sheet
COA/Test Release0
MAb to EBV EA-R MonoclonalPurifiedMouseIgG1EIA,IHC,IP,WBMGC65502M0.01 M Phosphate Buffered Saline, pH 7.2 Product contains no stabilizing protein.Infected Cell LysateNoMAb to EBV EA-R Monoclonal Antibody to Epstein Barr Virus (EBV) Early Antigen-R Homologue Bcl-2Safety Data Sheet
COA/Test Release0
MAb to Epstein Barr Virus MonoclonalPurifiedMouseIgG1IFA,WBMGC65221M0.01 M Phosphate Buffered Saline, pH 7.2 Product contains no stabilizing proteins.Infected B cell lysate (native protein).NoMAb to Epstein Barr Virus Monoclonal Antibody to Epstein-Barr Virus (EBV)Safety Data Sheet
COA/Test Release0
MAb to Epstein Barr Virus MonoclonalFITCMouseIgG1IFAMLC65223M0.01 M PBS, pH 7.2 containing 10 mg/mL BSAInfected B cell Lysate (Native Protein).NoMAb to Epstein Barr Virus Monoclonal Antibody to Epstein-Barr Virus (EBV), gp 220/350 Fluorescein ConjugatedSafety Data Sheet
COA/Test Release0
MAb to Epstein Barr Virus MonoclonalPurifiedMouseIgG2IFA,WB,IHCMGC65026M0.01 M PBS, pH 7.2 No stabilizing proteins have been added.Recombinant EB early antigen-diffuse.NoMAb to Epstein Barr Virus Monoclonal Antibody to Epstein-Barr Virus (EBV)Safety Data Sheet
COA/Test Release0
MAb to Epstein Barr Virus MonoclonalPurifiedMouseIgG1IFAMGC65023M0.01 M Phosphate Buffered Saline, pH 7.2 Product contains no stabilizing proteins.Infected B cell lysate (native protein).NoMAb to Epstein-Barr Virus Monoclonal Antibody to Epstein-Barr Virus (EBV)Safety Data Sheet
COA/Test Release0
Goat anti EBV Nuclear antigen PolyclonalPurifiedGoatN/AEIA,IFAMLB65102G0.01 M Phosphate Buffered Saline, pH 7.2 No stabilizing proteins have been added.Purified Recombinant EBNA-1NoGoat anti EBV Nuclear Antigen Goat Antibody to Epstein Barr Virus (EBV) Nuclear AntigenSafety Data Sheet
COA/Test Release0

Not seeing what you’re looking for? Inquire about a new product

Epstein-Barr Virus (EBV)

Primary EBV infections are typically asymptomatic and it is perhaps the most common reason for fever of unknown origin in young children. It does not occur in epidemics and has relatively low transmissibility, spreading mainly through bodily fluids (saliva). Approximately 90% of the US population is infected with EBV by the age of 25 and this infection rate is similar in other developed countries worldwide. EBV during pregnancy and transplacental transmission is rare. When infection with EBV occurs during adolescence or young adulthood, it causes infectious mononucleosis 35% to 50% of the time.

EBV is the first human virus to be directly implicated in carcinogenesis. Infection is associated with particular forms of cancer, such as Hodgkin’s lymphoma, Burkitt’s lymphoma, nasopharyngeal carcinoma, and conditions associated with AIDS including hairy leukoplakia and central nervous system lymphomas. In particular in Africa, the virus is associated with endemic Burkitt lymphoma in the setting of co-infection with Plasmodium falciparum. Specifically, it has been found that a malaria infection can impair the T-cell response to EBV and directly contribute to tumor pathogenesis.

Diagnosis

Diagnosing an EBV infection can be challenging since the symptoms are similar to other illnesses. However, different proteins are expressed during the various stages the EBV life cycle and the detection of these antigens can help distinguish whether an infection is a primary acute, convalescent, latent, or reactivation infection. About 90% of adults have antibodies that show that they have a current or past EBV infection. Diagnostic methods for EBV include IFA, ELISA, blot techniques, IgG avidity, PCR and virus isolation. Tests are available for detecting antibodies to the following EBV-associated antigens:

Viral capsid antigen (VCA):

  • Elevated anti-VCA IgM indicates acute infection (appears early in infection and usually disappears within 4 – 6 weeks)
  • Elevated anti-VCA IgG indicates prior infection (appears in the acute phase, peaks 2-4 weeks after onset, declines slightly, then persists for the rest of a person’s life)
  • Common VCA proteins are gp125 and p19

Early antigen (EA)

  • Anti-EA IgG appears in the acute phase of illness and generally falls to undetectable levels after 3-6 months
  • In many people, detection of antibody to EA is a sign of an active infection
  • 20% of healthy people may have antibodies against EA for several years

EBV nuclear antigen (EBNA)

  • Antibody to EBNA is not seen in the acute phase of EBV infection but slowly appears 2-4 months after onset of symptoms
  • Persists for the rest of a person’s life

Interested to learn more about COVID/Flu/RSV multiplex testing?

Get in Touch With A Specialist

Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.

Get In Touch With Us

Order a Sample